Kwality Pharmaceuticals has successfully filed and got the approval for Leuprorelin Acetate 11.25 mg vial powder and solvent for injectable suspension as a site variation in Greece, marking its entry into the European Markets. Kwality Pharma will supply the first three validation batches in December and after complete Quality Control Analysis, will start regular supplies from January 2025 onwards.
This strategic CDMO arrangement is projected to generate around $3 million of yearly sales, with distribution set to begin in the 4th quarter of this fiscal year. Furthermore, the company has plans to add remaining strengths of the same in the product portfolio with the same buyer as well. This marks a pivotal step in its strategy to introduce products in highly regulated markets.
Kwality Pharmaceuticals (formerly Kwality Pharmaceuticals) is a pharmaceutical formation company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: